Skip to main content

Cookies on the NHS England and NHS Improvement website

We’ve put some small files called cookies on your device to make our site work.

We’d also like to use analytics cookies. These send information about how our site is used to a service called Google Analytics. We use this information to improve our site.

Let us know if this is OK. We’ll use a cookie to save your choice. You canĀ read more about our cookies before you choose.

 

  • Home
  • News
  • Publications
  • Statistics
  • Blogs
  • Events
  • Contact us
NHS England
  • About us
  • Our work
  • Commissioning
  • Get involved
  • Insights Platform

Our advice for clinicians on the coronavirus is here.
If you are a member of the public looking for health advice, go to the NHS website. And if you are looking for the latest travel information, and advice about the government response to the outbreak, go to the GOV.UK website.

Infliximab for refractory or progressive neurosarcoidosis (adults and post-pubescent children)

Document first published:
9 July 2020
Page updated:
22 July 2020
Topic:
Commissioning, Medicine, Specialised commissioning
Publication type:
Policy or strategy, Report

Document

Clinical Commissioning Policy: Infliximab for refractory or progressive neurosarcoidosis (adults and post-pubescent children)

Clinical Commissioning Policy: Infliximab for refractory or progressive neurosarcoidosis (adults and post-pubescent children)

  • PDF
  • 228 KB
  • 10 pages

Document

Clinical panel report June 2019: Infliximab for refractory or progressive neurosarcoidosis (adults and post-pubescent children)

Clinical panel report June 2019: Infliximab for refractory or progressive neurosarcoidosis (adults and post-pubescent children)

  • PDF
  • 35 KB
  • 3 pages

Document

Clinical panel report February 2019: Infliximab for refractory or progressive neurosarcoidosis (adults and post-pubescent children)

Clinical panel report February 2019: Infliximab for refractory or progressive neurosarcoidosis (adults and post-pubescent children)

  • PDF
  • 25 KB
  • 1 pages

Document

Consultation report: Infliximab for refractory or progressive neurosarcoidosis (adults and post-pubescent children)

Consultation report: Infliximab for refractory or progressive neurosarcoidosis (adults and post-pubescent children)

  • PDF
  • 41 KB
  • 3 pages

Document

CPAG summary report: Infliximab for refractory or progressive neurosarcoidosis (adults and post-pubescent children)

CPAG summary report: Infliximab for refractory or progressive neurosarcoidosis (adults and post-pubescent children)

  • PDF
  • 58 KB
  • 6 pages

Document

Evidence review: Infliximab for refractory or progressive neurosarcoidosis (adults and post-pubescent children)

Evidence review: Infliximab for refractory or progressive neurosarcoidosis (adults and post-pubescent children)

  • PDF
  • 449 KB
  • 39 pages

Document

Stakeholder-engagement-report-refractory-or-progressive-neurosarcoidosis-(adults-and-post-pubescent-children)

Stakeholder-engagement-report-refractory-or-progressive-neurosarcoidosis-(adults-and-post-pubescent-children)

  • PDF
  • 39 KB
  • 3 pages
  • Terms and conditions
  • Privacy and cookies
  • Social media and comment moderation
  • How could this website work better for you?
  • Accessibility statement
  • Open Government Licence v3.0
  • Follow us on Twitter
  • Visit us on LinkedIn
  • Watch videos on YouTube
  • View photos on Flickr
  • All RSS
NHS website